Back to Search
ROHIT PARIHAR, M.D.
M.D.
Ophthalmology Physician
NPI: 1912134818IndividualAccepts Medicare
Specialties, Licenses & Credentials
Ophthalmology PhysicianPrimary
Ophthalmology
Code: 207W00000X
ME116731(FL)
CMS Specialties
PrimaryOPHTHALMOLOGY
Education
ST. LOUIS COLLEGE OF PHYSICIANS AND SURGEONS
Class of 2009
Research & Publications (20)
Satellite III non-coding RNAs show distinct and stress-specific patterns of induction.
PMID 19258006·Biochem Biophys Res Commun·2009
8-other
The malin-laforin complex suppresses the cellular toxicity of misfolded proteins by promoting their degradation through the ubiquitin-proteasome system.
PMID 19036738·Hum Mol Genet·2009
7-preclinical
Spatial positions of homopolymeric repeats in the human proteome and their effect on cellular toxicity.
PMID 19250635·Biochem Biophys Res Commun·2009
7-preclinical
Association between inflammatory gene polymorphisms and coronary artery disease in an Indian population.
PMID 18157711·J Thromb Thrombolysis·2009
8-other
Colocalization of the IL-12 receptor and FcgammaRIIIa to natural killer cell lipid rafts leads to activation of ERK and enhanced production of interferon-gamma.
PMID 18174382·Blood·2008
8-other
Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells.
PMID 16397268·Cancer Res·2006
7-preclinical
Interleukin-21 enhances NK cell activation in response to antibody-coated targets.
PMID 16785506·J Immunol·2006
7-preclinical
CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells.
PMID 16034101·J Immunol·2005
7-preclinical
Phase I study of the sequential combination of interleukin-12 and interferon alfa-2b in advanced cancer: evidence for modulation of interferon signaling pathways by interleukin-12.
PMID 16314644·J Clin Oncol·2005
3-trial
Src homology 2-containing inositol 5'-phosphatase 1 negatively regulates IFN-gamma production by natural killer cells stimulated with antibody-coated tumor cells and interleukin-12.
PMID 16204085·Cancer Res·2005
7-preclinical
Differential expression of SHIP1 in CD56bright and CD56dim NK cells provides a molecular basis for distinct functional responses to monokine costimulation.
PMID 15604218·Blood·2005
7-preclinical
Prolonged culture of vaccine-primed lymphocytes results in decreased antitumor killing and change in cytokine secretion.
PMID 15604282·Cancer Res·2004
7-preclinical
A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients.
PMID 15297404·Clin Cancer Res·2004
3-trial
The antitumor effects of IFN-alpha are abrogated in a STAT1-deficient mouse.
PMID 12865406·J Clin Invest·2003
7-preclinical
A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses.
PMID 12682258·J Immunol·2003
7-preclinical
A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661.
PMID 12473581·Clin Cancer Res·2002
3-trial
IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells.
PMID 12370276·J Clin Invest·2002
7-preclinical
Natural killer cells contribute to the lethality of a murine model of Escherichia coli infection.
PMID 12219013·Surgery·2002
7-preclinical
Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells.
PMID 11592078·Eur J Immunol·2001
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 502 E NEW HAVEN AVE
MELBOURNE, FL 32901 - Phone
- (321) 727-2020
Quick Facts
- NPI
- 1912134818
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 17
- Publications
- 20
Are you this provider?
Claim Your Profile